BEAM Q2 2023 Earnings — Beam Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BEAMBeam Therapeutics Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+20.8% YoY

Gross Profit

-$77M-385.2% margin

Operating Income

-$102M-507.8% margin

Net Income

-$83M-411.5% margin

EPS (Diluted)

$-1.08

QoQ Revenue Growth

-16.9%

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$101M

Stock-Based Comp.

$26M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$542M

Stockholders' Equity

$812M

Cash & Equivalents

$226M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$17M	+20.8%
Gross Profit	-$77M	-$58M	-33.8%
Operating Income	-$102M	-$82M	-24.6%
Net Income	-$83M	-$72M	-15.0%